ACAD

20.68

6.76% -1.50

Handel nachbörslich: 20.69 0.01 +0.05%

Acadia Pharmaceuticals Inc (ACAD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ACAD? Forum Prognose

Schlusskurs vom Vortag:

$22.18

Offen:

$22.21

24-Stunden-Volumen:

3.36M

Relative Volume:

1.89

Marktkapitalisierung:

$3.56B

Einnahmen:

$1.10B

Nettoeinkommen (Verlust:

$375.65M

KGV:

9.4158

EPS:

2.1963

Netto-Cashflow:

$113.59M

1W Leistung:

-24.22%

1M Leistung:

-32.35%

6M Leistung:

-6.04%

1J Leistung:

-2.50%

1-Tages-Spanne:

$20.61

$22.21

1-Wochen-Bereich:

$20.61

$27.43

52-Wochen-Spanne:

$19.69

$30.96

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Firmenname

Acadia Pharmaceuticals Inc

Sektor

Healthcare (1067)

Branche

Biotechnology (595)

Telefon

858-558-2871

Adresse

12830 EL CAMINO REAL, SAN DIEGO

Mitarbeiter

798

Twitter

@acadiapharma

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

ACAD's Discussions on Twitter

Compare ACAD vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACAD Acadia Pharmaceuticals Inc	20.68	3.56B	1.10B	375.65M	113.59M	2.1963
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-25	Hochstufung	BofA Securities	Neutral → Buy
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2026-02-23	Hochstufung	Mizuho	Neutral → Outperform
2025-10-21	Eingeleitet	Citigroup	Buy
2025-05-21	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-11	Eingeleitet	Deutsche Bank	Hold
2025-01-03	Herabstufung	Guggenheim	Buy → Neutral
2024-10-10	Fortgesetzt	Raymond James	Mkt Perform
2024-08-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-06-27	Eingeleitet	BMO Capital Markets	Outperform
2024-03-12	Herabstufung	Mizuho	Buy → Neutral
2024-03-12	Bestätigt	Needham	Buy
2024-01-30	Eingeleitet	Robert W. Baird	Outperform
2024-01-24	Hochstufung	Needham	Hold → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Herabstufung	Deutsche Bank	Buy → Hold
2023-12-13	Eingeleitet	Citigroup	Buy
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-11-06	Hochstufung	Mizuho	Neutral → Buy
2023-10-17	Eingeleitet	UBS	Buy
2023-10-10	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-03	Hochstufung	Guggenheim	Neutral → Buy
2022-11-04	Herabstufung	Goldman	Neutral → Sell
2022-11-01	Eingeleitet	Loop Capital	Hold
2022-08-08	Herabstufung	Citigroup	Buy → Neutral
2022-08-05	Herabstufung	Citigroup	Buy → Neutral
2022-06-21	Herabstufung	Jefferies	Buy → Underperform
2022-06-16	Hochstufung	Jefferies	Hold → Buy
2022-03-16	Hochstufung	Canaccord Genuity	Hold → Buy
2022-02-09	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-01-05	Hochstufung	Citigroup	Neutral → Buy
2021-12-21	Herabstufung	Guggenheim	Buy → Neutral
2021-11-01	Hochstufung	Guggenheim	Neutral → Buy
2021-10-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Fortgesetzt	Needham	Hold
2021-06-10	Eingeleitet	Berenberg	Hold
2021-04-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2021-04-06	Herabstufung	Canaccord Genuity	Buy → Hold
2021-04-06	Herabstufung	Goldman	Buy → Neutral
2021-04-06	Herabstufung	Jefferies	Buy → Hold
2021-04-06	Herabstufung	Mizuho	Buy → Neutral
2021-04-05	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-03-10	Herabstufung	BofA Securities	Buy → Neutral
2021-03-09	Herabstufung	Citigroup	Buy → Neutral
2021-03-09	Herabstufung	Guggenheim	Buy → Neutral
2021-03-09	Bestätigt	H.C. Wainwright	Buy
2021-03-09	Herabstufung	Raymond James	Strong Buy → Outperform
2021-03-09	Herabstufung	Stifel	Buy → Hold
2020-12-16	Eingeleitet	Mizuho	Buy
2020-11-16	Hochstufung	Raymond James	Outperform → Strong Buy
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-08-20	Eingeleitet	Morgan Stanley	Overweight
2020-07-07	Hochstufung	Stifel	Hold → Buy
2020-04-16	Eingeleitet	Jefferies	Buy
2020-03-31	Hochstufung	Goldman	Neutral → Buy
2020-03-06	Eingeleitet	Citigroup	Buy
2019-12-16	Eingeleitet	Guggenheim	Buy
2019-10-24	Eingeleitet	Oppenheimer	Perform
2019-10-01	Eingeleitet	RBC Capital Mkts	Outperform
2019-09-13	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Hochstufung	Canaccord Genuity	Hold → Buy
2019-07-23	Bestätigt	Needham	Buy
2018-12-10	Eingeleitet	Canaccord Genuity	Hold
2018-09-21	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-08-09	Bestätigt	Stifel	Hold
2018-08-07	Eingeleitet	Stifel	Hold
2018-08-06	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

04:46 AM

Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st

04:46 AM

Sep 25, 2026

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - 기업경제뉴스

Sep 25, 2026

Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus

Sep 25, 2026

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha

Sep 25, 2026

Acadia push in ADP still alive after near miss in phase II - BioWorld News

Sep 25, 2026

Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - finance.yahoo.com

Sep 25, 2026

ACAD Maintains Buy Rating -- Price Target Lowered to $33.00 by HC Wainwright - GuruFocus

Sep 25, 2026

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - finance.yahoo.com

Sep 25, 2026

Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss - finance.yahoo.com

Sep 25, 2026

ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co. - Moomoo

Sep 25, 2026

HC Wainwright & Co. maintains Buy rating on ACADIA Pharmaceuticals, $33 price target - TradingView

Sep 25, 2026

Needham cuts Acadia Pharmaceuticals stock price target on trial results By Investing.com - Investing.com Nigeria

Sep 25, 2026

Citizens maintains Market Outperform rating on ACADIA Pharmaceuticals, $33 price target - TradingView

Sep 25, 2026

Needham cuts Acadia Pharmaceuticals stock price target on trial results - Investing.com India

Sep 25, 2026

ACAD Maintained by Needham -- Price Target Lowered to $35 - GuruFocus

Sep 25, 2026

Citizens cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada

Sep 25, 2026

Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ

Sep 25, 2026

Sep 24, 2026

ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - finance.yahoo.com

Sep 24, 2026

Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - tikr.com

Sep 24, 2026

Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis - insights.citeline.com

Sep 24, 2026

ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - finance.yahoo.com

Sep 24, 2026

Acadia Reports Phase 2 Data for Alzheimer’s Psychosis - TipRanks

Sep 24, 2026

Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance - TradingView

Sep 24, 2026

Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily

Sep 24, 2026

ACADIA Pharma's price target cut after mixed Al... - Pluang

Sep 24, 2026

Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss - Investing.com Canada

Sep 24, 2026

TD Cowen reiterates Acadia Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada

Sep 24, 2026